To further explore the potential molecular mechanism of the protective effect of EchA in diabetic nephropathy in vivo, the activity of the PKCι/p38 MAPK pathway and its downstream targets, such as p53 and c-Jun, was examined. Here, TP53 is linked to diabetic kidney disease.